Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension
Abstract This study assessed the efficacy and safety of sacubitril/valsartan in 23 hemodialysis patients with hypertension (mean age 70 years; male 69.6%) after switching from azilsartan, an angiotensin receptor blocker. Both at baseline and 3 months after the start of sacubitril/valsartan treatment...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | The Journal of Clinical Hypertension |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jch.14635 |
| _version_ | 1827778884667441152 |
|---|---|
| author | Yoshio Iwashima Hiromichi Fukushima Takeshi Horio Tatemitsu Rai Toshihiko Ishimitsu |
| author_facet | Yoshio Iwashima Hiromichi Fukushima Takeshi Horio Tatemitsu Rai Toshihiko Ishimitsu |
| author_sort | Yoshio Iwashima |
| collection | DOAJ |
| description | Abstract This study assessed the efficacy and safety of sacubitril/valsartan in 23 hemodialysis patients with hypertension (mean age 70 years; male 69.6%) after switching from azilsartan, an angiotensin receptor blocker. Both at baseline and 3 months after the start of sacubitril/valsartan treatment, home blood pressure (BP), BP values during hemodialysis, and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) level were measured. The mean dosage of azilsartan was 30 ± 10 mg/day at baseline and that of sacubitril/valsartan after 3 months of treatment was 204 ± 64 mg/day. After 3 months, significant reductions in mean morning home BP (155 ± 17/80 ± 12 to 147 ± 16/76 ± 11 mmHg), mean nighttime home systolic BP (153 ± 19 to 144 ± 16 mmHg), and median (IQRs) NT‐proBNP level [8124 (2620–13 394) to 6271 (1570–9591) pg/mL] were observed (all P < .05), whereas BP values during hemodialysis did not change significantly. In hemodialysis patients, except for hypotension, sacubitril/valsartan was generally well tolerated, effectively controlled out‐of‐office BP, and improved NT‐proBNP. |
| first_indexed | 2024-03-11T14:42:14Z |
| format | Article |
| id | doaj.art-70536cc0a9a7498590ff74807d416b78 |
| institution | Directory Open Access Journal |
| issn | 1524-6175 1751-7176 |
| language | English |
| last_indexed | 2024-03-11T14:42:14Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Journal of Clinical Hypertension |
| spelling | doaj.art-70536cc0a9a7498590ff74807d416b782023-10-30T13:26:48ZengWileyThe Journal of Clinical Hypertension1524-61751751-71762023-03-0125330430810.1111/jch.14635Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertensionYoshio Iwashima0Hiromichi Fukushima1Takeshi Horio2Tatemitsu Rai3Toshihiko Ishimitsu4Department of Internal Medicine Kansai Medical University Kori Hospital Neyagawa Osaka JapanDivision of Internal Medicine Mooka Hospital Mooka Tochigi JapanDepartment of Cardiovascular Medicine Ishikiriseiki Hospital Higashiosaka Osaka JapanDepartment of Nephrology and Hypertension Dokkyo Medical University Mibu Tochigi JapanDepartment of Nephrology and Hypertension Dokkyo Medical University Mibu Tochigi JapanAbstract This study assessed the efficacy and safety of sacubitril/valsartan in 23 hemodialysis patients with hypertension (mean age 70 years; male 69.6%) after switching from azilsartan, an angiotensin receptor blocker. Both at baseline and 3 months after the start of sacubitril/valsartan treatment, home blood pressure (BP), BP values during hemodialysis, and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) level were measured. The mean dosage of azilsartan was 30 ± 10 mg/day at baseline and that of sacubitril/valsartan after 3 months of treatment was 204 ± 64 mg/day. After 3 months, significant reductions in mean morning home BP (155 ± 17/80 ± 12 to 147 ± 16/76 ± 11 mmHg), mean nighttime home systolic BP (153 ± 19 to 144 ± 16 mmHg), and median (IQRs) NT‐proBNP level [8124 (2620–13 394) to 6271 (1570–9591) pg/mL] were observed (all P < .05), whereas BP values during hemodialysis did not change significantly. In hemodialysis patients, except for hypotension, sacubitril/valsartan was generally well tolerated, effectively controlled out‐of‐office BP, and improved NT‐proBNP.https://doi.org/10.1111/jch.14635hemodialysishome blood pressureN‐terminal pro‐brain natriuretic peptidesacubitril/valsartan |
| spellingShingle | Yoshio Iwashima Hiromichi Fukushima Takeshi Horio Tatemitsu Rai Toshihiko Ishimitsu Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension The Journal of Clinical Hypertension hemodialysis home blood pressure N‐terminal pro‐brain natriuretic peptide sacubitril/valsartan |
| title | Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension |
| title_full | Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension |
| title_fullStr | Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension |
| title_full_unstemmed | Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension |
| title_short | Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension |
| title_sort | efficacy and safety of sacubitril valsartan after switching from azilsartan in hemodialysis patients with hypertension |
| topic | hemodialysis home blood pressure N‐terminal pro‐brain natriuretic peptide sacubitril/valsartan |
| url | https://doi.org/10.1111/jch.14635 |
| work_keys_str_mv | AT yoshioiwashima efficacyandsafetyofsacubitrilvalsartanafterswitchingfromazilsartaninhemodialysispatientswithhypertension AT hiromichifukushima efficacyandsafetyofsacubitrilvalsartanafterswitchingfromazilsartaninhemodialysispatientswithhypertension AT takeshihorio efficacyandsafetyofsacubitrilvalsartanafterswitchingfromazilsartaninhemodialysispatientswithhypertension AT tatemitsurai efficacyandsafetyofsacubitrilvalsartanafterswitchingfromazilsartaninhemodialysispatientswithhypertension AT toshihikoishimitsu efficacyandsafetyofsacubitrilvalsartanafterswitchingfromazilsartaninhemodialysispatientswithhypertension |